ConductScience.org, home

Paper42732142

What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.

Martyn E and 14 others. Wellcome Open Res, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol. Papers, record 42732142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42732142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.
PubMed
Journal
Wellcome Open Res
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-04
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martyn EEmilyhttps://orcid.org/0000-0003-4981-9298
2Carter JJessica
3Barlow MMaevehttps://orcid.org/0000-0003-1161-8335
4Olcott FFlora
5Ghosh IIndrajithttps://orcid.org/0009-0009-5311-9885
6Waddilove EElizabeth
7Arenas-Pinto AAlejandro
8Gilson RRichard
9Flanagan SStuart
10Venter WFWd Francois
11Manne-Goehler JJennifer
12Hargreaves SSally
13Tsochatizis EEmmanouil
14MacDonald DDouglas
15Matthews PCPhilippa Chttps://orcid.org/0000-0002-4036-4269

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CC2223Wellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138577526Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis.World J Hepatol2024https://conductscience.org/library/papers/38577526PubMed
230006442Ten simple rules for conducting umbrella reviews.Evid Based Ment Health2018https://conductscience.org/library/papers/30006442PubMed
338429161Current status and future trends of the global burden of MASLD.Trends Endocrinol Metab2024https://conductscience.org/library/papers/38429161PubMed
428935701AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.BMJ2017https://conductscience.org/library/papers/28935701PubMed
536625022The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis.Expert Rev Gastroenterol Hepatol2023https://conductscience.org/library/papers/36625022PubMed
624581293Systematic review finds overlapping reviews were not mentioned in every other overview.J Clin Epidemiol2014https://conductscience.org/library/papers/24581293PubMed
738356666Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis.Exp Ther Med2024https://conductscience.org/library/papers/38356666PubMed
836727674AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023https://conductscience.org/library/papers/36727674PubMed
935192111Liver biopsy for assessment of chronic liver diseases: a synopsis.Clin Exp Med2023https://conductscience.org/library/papers/35192111PubMed
1040227096The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis.Hepatol Commun2025https://conductscience.org/library/papers/40227096PubMed
1131903714Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?Liver Int2020https://conductscience.org/library/papers/31903714PubMed
1238432237Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.Lancet2024https://conductscience.org/library/papers/38432237PubMed
1325662901Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.Lancet Neurol2015https://conductscience.org/library/papers/25662901PubMed
1437533208Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis.J Viral Hepat2023https://conductscience.org/library/papers/37533208PubMed
1536111362Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis.Hepatology2023https://conductscience.org/library/papers/36111362PubMed
1639488409Steatotic liver disease.Lancet2024https://conductscience.org/library/papers/39488409PubMed
1740638020
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis.
Infect Dis Ther2025https://conductscience.org/library/papers/40638020PubMed
1837157776Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.Clin Mol Hepatol2023https://conductscience.org/library/papers/37157776PubMed
1940707650Viral hepatitis: breaking down barriers.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/40707650PubMed
2037364816A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Ann Hepatol2024https://conductscience.org/library/papers/37364816PubMed

See all 34 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42732142What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.Wellcome Open Res2026https://conductscience.org/library/papers/42732142

Source PubMed

Download CSV of cited by

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
figshare10.6084/m9.figshare.31981305

Source figshare

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42732142

GET https://conductscience.org/api/papers/v1/42732142/references?page=2